

Case Docket No. <u>GTN-001</u>



08/487,032

June 7, 1995

NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER PLYORI FOR DIAGNOSTICS. AND THERAPEUTICS

ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

Transmitted herewith for filing in connection with the above-identified application are the following:

- Response to Notice to File Missing Parts of Application (in duplicate)
- ☑ One executed Declaration, Petition and Power of Attorney
- ☑ Preliminary Amendment
- Sequence Listing substitute pages 76 through 782
- ▼ Transmittal Letter for Diskette for Sequence Listing
- □ Diskette Containing Sequence Listing
- **区** Copy of PTO Form 1533
- Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures
- Request for Three-Month Extension of Time (in duplicate)
- ☐ Check in the amount of \$860.00 (missing parts and surcharge fee)
- Check in the amount of \$900.00 (extension fee)
- ☐ Check in the amount of \$2488.00 (presentation of extra claims)
- Return postcard

The fee has been calculated as shown below:

(Col. 1)				(Col. 2)			(Col. 3)	
		AIMS REMAINING TER AMENDMENT			GHEST NO. 'IOUSLY PAID FOR		PRESENT EXTRA	
TOTAL	*	87	MINUS	**	20	1	67	
INDEP.	*	16	MINUS	***	3	11	13	
☐ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM								

SWIALL CHILL				
RATE	ADDIT. FEE			
x 11 =	\$.00			
x 39 =	\$.00			
+125 =	\$.00			
TOTAL ADDIT, FEE	\$0.00			

SMALL ENTITY

SMALL ENTITY					
RATE	ADDIT. FEE				
x 22 =	\$ 1474.00				
x 78 =	\$ 1014.00				
+ 250 =	\$.00				
TOTAL	\$2488.00				

OTHER THAN A

<u>OR</u>

<u>or</u>

- If the entry in Col 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

Amendment Transmittal Serial No. 08/487,032 Page 2

Please charge any additional fees or credit any overpayments associated with this communication to our Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on:

Date

Amy E Mandragouras, Reg. No. 36,20

Respectfully submitted,

LAHIVE & COCKFIELD

Amy E. Mandragouras

Reg. No. 36, 207

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

the application of: Smith, Douglas

Serial No.: 08/487,032

Filed: June 7, 1995

For: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER PYLORI FOR DIAGNOSTICS AND THERAPEUTICS

Attorney Docket No.: GTN-001

Examiner:

Group Art Unit:

LOC 026

Assistant Commissioner for Patents BOX MISSING PARTS Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents. Washington, D.C. 20231 on the date set forth below.

Date of Signature and of Mail Deposit

Amy E. Mandragouras Registration No. 36,207

Attorney for Applicant

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

Dear Sir:

Responsive to the Notice to File Missing Parts of Application dated September 17, 1995,

Applicant's attorney submits herewith the executed Declaration, Petition and Power of Attorney

for Pate Application and a check in the amount of \$860.00 to cover the total amount owed by

Applicant including the \$130.00 surcharge and the \$730.00 basic filing fee. A Preliminary

Amendment, Sequence Listing in computer readable form as required by 37 CFR 1.821(e),

Sequence Listing as required under 37 CFR 1.821(c), a copyoof Form P/FO 0653203 and a copy of

1.014.00 CK

1 103 1.474.00 CK Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures are also enclosed.

-2-

The Commissioner is hereby authorized to charge payment of any fees under 37 C.F.R. 1.16 and 1.17 during the pendency of this application or credit any overpayment to Deposit Account No. 12-0080.

Please charge any underpayments or credit any overpayments associated with this communication to our Deposit Account No. 12-0080. A duplicate of this letter is enclosed.

Respectfully submitted,

LAHIVE & COCKFIELD

Amy E. Mandragouras Registration No. 36,207 Attorney for Applicants

60 State Street Boston, MA 02109 Tel. (617) 227-7400

Dated: December 15, 1995



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Smith, Douglas

Serial No.: 08/487,032

Filed: June 7, 1995

For: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER PYLORI FOR DIAGNOSTICS AND THERAPEUTICS

Attorney Docket No.: GTN-001

BOX SEQUENCE

Assistant Commissioner for Patents Washington, D.C. 20231

Group Art Unit:

Examiner:

TRANSMITTAL LETTER FOR DISKETTE OF SEQUENCE LISTING

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated September 17, 1995, we enclose a diskette which contains a computer readable form of the Sequence Listing for the above-referenced application. The Sequence Listing complies with the requirements of 37 C.F.R. §§1.821 and 1.825. The material on this diskette is identical in substance to the paper copy of the Sequence Listing which is submitted herewith. The computer readable form of the Sequence Listing contained on the enclosed diskette is understood to comply with the requirement of §1.824(d). No new matter has been added.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Sequence, Assistant Commissioner for Patents, Washington, DC 20231 on:

December 15, 1995

Amy E. Mandragouris, Reg. No. 36,207

Respectfully submitted,

LAHIVE & COCKFIELD

Amy E. Mandragouras

Reg. No. 36,207 60 State Street

Boston, MA 0209

Tel. (617 227-7400

	*'	
•		pplication No
, NC	NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APP NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DIS	LICATIONS CONTAINING
The	The nucleotide and/or amino acid sequence disclosure contained in this application do for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):	
	This application clearly fails to comply with the requirements of 37 CFR 1.821 directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55	- 1.825. Applicant's attention is FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper required by 37 CFR 1.821(c). —	er copy, a "Sequence Listing" as
abla	3. A copy of the "Sequence Listing" in computer readable form has not been sub	mitted as required by 37 CFR 1.321(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted computer readable form does not comply with the requirements of 37 CFR 1.822 attached marked-up copy of the "Raw Sequence Listing."	ed. However, the content of the and/or 1.823, as indicated on the
	5. The computer readable form that has been filed with this application has been unreadable as indicated on the attached CRF Diskette Problem Report. A substituted as required by 37 CFR 1.825(d).	found to be damaged and/or ute computer readable form must be
	6. The paper copy of the "Sequence Listing" is not the same as the computer read as required by 37 CFR 1.821(e).	dable form of the "Sequence Listing"
	.7. Other: ————————————————————————————————————	
Appi	oplicant must provide:	
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing	-
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specification	
	A statement that the content of the paper and computer readable copies are the sa new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1	me and, where applicable, include no825(d)
	r questions regarding compliance with these requirements, please c	
For R	r Rules Interpretation, call (703) 308-1123 r CRF submission help, call (703) 308-4212 r Patentin software help, call (703) 308-6856	·.

Please return a copy of this notice with your response.